Outcomes of patients from restricted (Group 1) and non-restricted (Group 2) COVID-19 period with newly diagnosed nAMD of the first eye who have received aflibercept 2mg injections only.

Outcomes of patients from restricted (Group 1) and non-restricted (Group 2) COVID-19 period with newly diagnosed nAMD of the first eye who have received aflibercept 2mg injections only.

<p>Outcomes of patients from restricted (Group 1) and non-restricted (Group 2) COVID-19 period with newly diagnosed nAMD of the first eye who have received aflibercept 2mg injections only.</p>

Saved in:

Bibliographic Details
Main Author:	Mike Y. Chen (13881956) (author)
Other Authors:	Jeanette Du (21261953) (author), Brian K. Do (21261956) (author), Mohsin H. Ali (21261959) (author)
Published:	2025
Subjects:	Medicine Cell Biology Neuroscience Biotechnology Immunology Developmental Biology Cancer Science Policy Infectious Diseases Computational Biology related macular degeneration corrected visual acuity 19 restrictions period worse visual outcomes comparing visual outcomes 376 subjects diagnosed 258 subjects diagnosed reduced treatment frequency mean bcva improved final mean bcva group 2 ). group 2 primary outcomes mean change diagnosed thereafter final best median bcva logmar bcva bcva ), retina group group 1 086 ). 010 ). 007 ). 004 ). xlink "> versus 48 two groups retrospective study namd treatment multiple factors march 2022 march 2020 likely contributed first year 67 vs
Tags:	Add Tag No Tags, Be the first to tag this record!

Cannot write session to /tmp/vufind_sessions/sess_gjr418tlqi80h9ccgas3adqvv7